Psoriasis (Pso)

HKB's NHP Psoriasis Models offer pharmaceutical companies advanced translational platforms for developing novel psoriasis therapeutics. Our non-human primate models replicate key pathological features of psoriasis, including epidermal hyperplasia, parakeratosis, and inflammatory cell infiltration. These models are extensively validated with established endpoints such as PASI scoring, histopathological analysis, and cytokine profiling. The close evolutionary relationship between NHPs and humans ensures superior predictive value for clinical outcomes. With GLP/AAALAC certification and comprehensive regulatory documentation, our psoriasis models support seamless transition from preclinical studies to IND submissions.